Reta-20 (Retatrutide)

Description

Reta-20 (Retatrutide)
20 mg · Lyophilized · Research Grade

Triple Agonist Architecture. Next-Generation Metabolic Research.

Retatrutide (LY3437943) is a triple receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors — one of the most structurally sophisticated peptide compounds currently under advanced clinical investigation in metabolic medicine and obesity research.

Each vial contains 20 mg of lyophilized Retatrutide, synthesized to pharmaceutical-reference standards and confirmed at ≥98% purity by HPLC with independent MS verification.

Purity: ≥98% HPLC
Format: Lyophilized powder
Vial: 20 mg
Storage: −20°C long-term / 2–8°C up to 4 weeks
Targets: GLP-1R · GIPR · Glucagon Receptor
Includes: Certificate of Analysis · HPLC Report · MS Confirmation

For Research Use Only. Not for human administration.